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Prescribing for Children 
Abstract 
In this article in the series of ‘bite sized’ pharmacology, we will look at the pharmacological 
considerations when prescribing for children. This article will illustrate the common issues to 
consider when prescribing for the under 18 (or more often than not the under 12) population. 
The primary focus will be on pharmacokinetics and the four processes that occur after oral 
drug administration, with specific details on the factors that affect these processes in this 
patient group. There will also be some consideration of legal aspects and consent to treatment 
including concordance and a brief area on licensing. Exercises provided will help you apply 
this knowledge to your prescribing practice.  
 
We must remember as prescribers that a drug has to be: 
 Available in a suitable form 
 Administered by an appropriate route 
 Absorbed into the body fluids and tissues 
 Distributed to its active site 
 Metabolised, primarily by the liver 
 Excreted, primarily by the kidneys 
These actions that occur after administration are pharmacokinetics and we shall begin by 
exploring the differences in this population of patient as this is an area of significant 
consideration for the prescriber. 
 
Pharmacokinetics is the action of the body on the drugs that we take. It can be broken down 
into four processes as can be seen from table 1. (More detail on each of these processes is 
found in the article on pharmacokinetics in Volume 15, issue3). 
  
Table 1- The four pharmacokinetic processes that occur after oral drug administration 
A- Absorption of the drug 
D- Distribution of the drug molecules 
M- Metabolism of the parent drug 
E- Excretion of the drug and its metabolites 
As we have done in a previous article in this series (Robertson, D. 2018), we will consider the 
seven principles of good prescribing practice when dealing with children. 
Prescribing Pyramid (NPC 1999)
When considering prescribing for children, it is important to remember that dependent on the 
age and understanding of the child, information may need to be gathered in a different way, 
from someone other than the child themselves, and how you interpret and use this 
information may be different. We will go on to explore the relevant areas of this framework.  
 
Exercise 
Using the BNF, look up the section on prescribing in children. Review all the areas it 
discusses and reflect on how these may correlate with your area of prescribing. 
Consider the Patient 
Consideration of the patient should be modified to reflect the additional considerations 
required in the child. The age of the child and their stage of development both emotionally, 
physically and cognitively need to be factored in.  
The main factors to consider in addition to normal consultation and examination are; 
 
• Development of the normal pharmacokinetic processes 
• Small size and weight 
• Formulation of medication 
• Ability of child to take medication 
• Compliance considerations- child and responsible adult 
• School and medicine administration issues 
 
 
Pharmacokinetics Considerations 
 
Absorption 
Absorption of drugs from all administration routes except intravenous is required to get the drug from 
the site of administration to the blood stream. There are some specific considerations when 
prescribing in children.  
There can be some issues in using the oral route of administration 
 In young infants, gastric emptying time is often prolonged and only approaches adult values 
at around 6 months of age.  
 Increased gastric pH: gastric acid output does not reach adult values until the second year of 
life so the gastric fluid environment is not as acidic. 
 Other factors: gastrointestinal contents (related to feeding; especially if ‘demand’ feeding, and 
stage of weaning), posture (position of child and head stability related to age and 
development), disease states (for example pyloric stenosis or infant reflux) and therapeutic 
interventions, such as drug therapy or feeding tubes, can also affect the absorption process. 
 Some children, of many ages have problems swallowing tablets and this may mean that either 
liquid preparations should be considered or if severe problems encountered, then another 
route of administration may be required. 
 
Distribution 
Distribution of drugs from the plasma to cell and tissues can be compromised due to any or a 
combination of the following factors 
 Increased total body water: as a percentage of total body weight, the total body water and 
extracellular fluid volume of the child decreases with increasing age. Neonates require higher 
doses of water-soluble drugs, on an mg/kg basis, than adults. 
 Decreased plasma protein binding: plasma protein binding in neonates is reduced as a result 
of low levels of albumin and globulins and an altered binding capacity meaning that there is 
more ‘free drug’ available and dosing should be considered to allow for this to avoid toxicity. 
 The presence of high levels of bilirubin in the circulation of the neonate can affect binding to 
plasma proteins, this is usually only a problem in the first few days of life as the liver function 
increases and adapts, even in the child not needing phototherapy for high bilirubin levels but 
with a degree of jaundice present.  
 Neonates have less efficient skin barrier meaning topical preparations are more readily 
absorbed and they have a more permeable blood-brain barrier allowing easy passage of drugs 
into the central nervous system 
 
 
 
Metabolism 
Drug metabolism primarily occurs in the liver 
 Enzyme systems mature at different times and may be absent at the time of birth, or present in 
considerably reduced amounts, especially in pre-term infants. This can be compounded if 
there a high levels of circulating bilirubin as the liver adapts to its role in the independent 
baby as oppose to the dependent foetus. 
 Cytochrome P450 metabolic enzyme expression is lower in neonates and increases with age 
and development. Adult values can be reached by an average of 2 years of age. Some drug 
metabolising enzymes for certain drugs, such as the phenobarbital, take longer to mature and 
prescribing for these drugs should be done with caution (Ku & Smith 2015) 
 
Excretion 
 Glomerular filtration, active tubular secretion and tubular reabsorption reduced at birth but 
clearance increases with age to near adult values by 6-12 months in the term infant. 
 Lower values are seen in pre term infants and maturation occurs later 
 (Ku & Smith 2015) 
Pharmacological considerations may influence the ‘Choice of Product’ area of the framework 
and impact on the ‘Strategy’ and ‘Negotiate a Contract’ aspects also.  
 
Exercise 
Using the BNF, or other drug resource, look up a drug you are likely to prescribe in practice. 
Identify if there are any restrictions on prescribing in children, infants or neonates. Reflect on 
any changes you would need to make to dose or prescribing regimes in light of this.  
 
Other Areas to be Aware of 
Dosages and Dosing Regimens 
 Paediatric doses should be obtained from a paediatric dosage reference text, such as the 
BNFC or local paediatric formularies and not extrapolated from the adult dose. 
 Unless the age is specified, the term 'child' in the BNFC includes persons aged 12 years and 
younger. This can be broken down into prescribing age ranges as follows; 
• neonate (birth to 1 month) 
• infant (1 month to 2 years) 
• child (2 to 12 years) 
 
Compliance and Concordance 
Compliance with the prescribed medication in children can be influenced by many factors, 
which often differ from factors that affect adult compliance with medication. Children may 
not be able themselves to consent to medication taking and often the parent or guardian is 
approached for consent. In an older child it may be appropriate to check capacity to consent 
using Fraser Guidelines to see if the child is Gillick competent in their acceptance or refusal 
of treatment (Gillick 1984).  
We should still always try to reach a concordant agreement and this falls under the ‘Negotiate 
a Contract’ section of the prescribing pyramid.  It should also be considered at the ‘Review’ 
stage. 
 
 Compliance in children can be influenced by the formulation, taste, appearance and ease of 
administration of a preparation. 
 Prescribed regimens should, where possible be tailored to the child's daily routine accounting 
for age appropriate factors such as school or nursery and feeding regimes. 
 Treatment goals should be set in collaboration with the child where it is feasible to do so, or 
with the parent or guardian where this is more appropriate. 
 Whenever possible, the use of products which avoid the need for administration during school 
hours should be considered (e.g. modified-release preparations or drugs with long half-lives). 
When administration at school is unavoidable, consideration should be given to the 
information and supply to conform to school regulations. 
 Children with ongoing need for medication due to long term conditions should have a health 
care plan for school. 
 Avoid painful intramuscular injections where possible 
 
Exercise 
Can you identify factors for the children in your area of practice that might affect their ability to 
comply with or adhere to the medication regimes? Reflect on how you could manage these from a 
pharmacological and prescribing perspective.  
 
Product Licensing 
The BNF states that wherever possible, medicines for children should be prescribed within 
the terms of the marketing authorisation, also known as the product license. It is however 
widely acknowledged that many medications are not specifically licensed for paediatric use 
and this has to be taken into account by the prescriber when prescribing medications that are 
needed but have no specific paediatric license. It is recognised and accepted that the informed 
use of licenced medicines out with the terms of their product licence (off-license or off-label 
use) is often necessary in paediatric practice.  
Prescription Writing 
There are specifics with regards to prescription writing requirements in primary care for the 
child under 12. This comes under the ‘Record Keeping’ area of the pyramid. 
 Inclusion of age on the prescription FP-10 is a legal requirement in the case of prescription-
only medicines for children under 12 years of age. It is good practice to state the age for all 
prescriptions for children. If the child is under 5 years old, then the age must be stated in 
years and months. 
 Wherever appropriate the prescriber should state the current weight of the child to enable the 
dose prescribed to be checked. 
 It is important to state the strengths of capsules or tablets or liquid medication and prescribe 
the dose to be given e.g. in mg rather than the amount in ml 
  Liquid preparations may contain sugar which encourages dental decay. Sugar-free medicines 
are preferred for long-term treatment. 
 
Adverse Drug Reactions & Reporting In Children 
As with other patients the reporting of suspected adverse drug reactions should be done via 
the Yellow Card Scheme. The identification of adverse effects in children is particularly 
important as the effects pharmacologically in children may differ from those in adults. We 
have less knowledge around a child’s response to medications as many drugs have not been 
tested in children. The effects of a drug on a child’s growth and development can be seen as 
delayed adverse reactions and may be reported after the fact. 
 
 
 
 
Exercise 
Using a BNF or other resource identify any specific prescription writing requirements for a 
drug from your area of practice in a child or neonate. Then go on to identify if possible any 
special licensing information for paediatric use. 
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